Table 1 Characteristics of the included studies
Author | Country | Year | Article type | Design | Indication | Age | Sample size | Male(%) | Follow-up(M) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LBBaP/HBP | BVP | LBBaP/HBP | BVP | LBBaP/HBP | BVP | |||||||
Lustgarten et al. | U. S | 2015 | Randomized trial | HBP vs BVP | QRS > 130 ms | 71.3 (55.91–86.75) | 71.3 (55.91–86.75) | 12 | 12 | 66.7 | 66.7 | 6 |
Upadhyay et al. | U. S | 2019 | Randomized trial | HBP vs BVP | NYHA II-IV with QRS > 120 ms | 63.4 ± 13.3 | 65.5 ± 12.4 | 16 | 24 | 56.2 | 66.7 | 6 |
Vijayaraman et al. | U. S | 2019 | Observational study | HBP vs BVP | NYHA III-IV, LVEF ≤ 35%, LBBB and IVCD with QRS ≥ 140 ms | 72 ± 15 | 72 ± 15 | 27 | 27 | 85 | 85 | 14 |
Li et al. | China | 2020 | Observational study | LBBaP vs BVP | HF, LVEF ≤ 35%, LBBB | 57.5 ± 9.8 | 58.5 ± 8.5 | 27 | 54 | 51.9 | 61.1 | 6 |
Guo et al. | China | 2020 | Observational study | LBBaP vs BVP | HF, LVEF ≤ 35%, LBBB, NYHA II-IV | 66.1 ± 9.7 | 65.1 ± 7.5 | 21 | 21 | 42.9 | 42.9 | 6 |
Wang et al. | China | 2020 | Observational study | LBBaP vs BVP | HF, CLBBB with QRS > 130 ms, LVEF ≤ 35%, NYHA II-IV | 64.8 ± 7.25 | 62.9 ± 10.33 | 10 | 30 | 90 | 76.6 | 6 |
Chen et al. | China | 2021 | Observational study | LBBaP vs BVP | HF, LBBB with QRS > 150 ms, LVEF ≤ 35%, NYHA II-IV | 67.14 ± 8.88 | 64.37 ± 8.74 | 49 | 51 | 49.98 | 58.82 | 12 |
Wu et al. | China | 2021 | Observational study | LBBaP or HBP vs BVP | HF, LVEF ≤ 40%, CLBBB | 67.2 ± 13/68.3 ± 10 | 68.3 ± 10 | 32/49 | 54 | 43.8/63.3 | 53.7 | 12 |
Ma et al. | China | 2021 | Observational study | HBP vs BVP | Brady-arrhythmia, Permanent AF and HF with HFrEF | 70.32 ± 12.36 | 66.8 ± 7.26 | 37 | 15 | 70.27 | 66.7 | 18 |
Vinther et al. | Denmark | 2021 | Randomized trial | HBP vs BVP | HF with LVEF ≤ 35%, NYHA II-IV, LBBB with QRS > 130 ms | 63.2 ± 9.2 | 67.4 ± 9.1 | 19 | 31 | 42 | 77 | 6 |
Zizek et al. | Slovenia | 2021 | Observational study | HBP vs BVP | Permanent AF, 35% ≤ LVEF < 50%, QRS ≤ 120 ms,NYHA II-III | 68.5 ± 6.8 | 69.3 ± 6.6 | 12 | 12 | 41.7 | 58.3 | 6 |
Hua et al. | China | 2022 | Observational study | LBBaP vs BVP | HF with NYHA II-IV, QRS ≥ 150, CLBBB | 65.5 ± 6.91 | 67.5 ± 11.69 | 21 | 20 | 15 | 16 | 24 |
Vijayaraman et al. | U. S | 2022 | Observational study | CSP vs BVP | LVEF ≤ 35% with class II-IV heart failure symptoms | 72 ± 13 | 72 ± 12 | 258 | 219 | 170 | 156 | 27 |